Business Context and Reporting Period
Altimmune, Inc. filed a Form 8-K Current Report on April 2, 2020, regarding a material definitive agreement entered into on that date. The Company is a Delaware corporation with its principal executive offices in Gaithersburg, Maryland.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a new contractual agreement.
Material Changes
On April 2, 2020, Altimmune entered into Amendment No. 3 to its Second Restated License Agreement with Janssen Vaccines & Prevention B.V. Key changes include:
- Expanded License Field: The agreement now covers COVID-19 caused by SARS-CoV-2, in addition to existing licenses for Bacillus anthracis and influenza virus.
- Milestone Payments: The Company agreed to pay development-based milestone payments upon FDA approval of licensed products for COVID-19, totaling up to approximately $1.225 million.
- Royalty Obligations: The Company agreed to pay royalties as a percentage of net sales for COVID-19 products in countries covered by licensed patents or know-how. These payments are subject to royalty stacking reductions and minimum annual royalty requirements until the agreement expires.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future outlook, or a discussion of general risks. The primary contingency noted is the Company's obligation to file the full text of the Amendment as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2020.
Investor Verification Checklist
- Verify the specific conditions triggering the $1.225 million in milestone payments.
- Review the full text of Amendment No. 3 in the upcoming Form 10-Q to understand royalty stacking reduction mechanics and minimum annual royalty thresholds.
- Confirm the scope of "licensed know-how" and patent claims applicable to the new COVID-19 field.